Clinical Trial

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 21, 2023 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Patients with newly diagnosed MCL were treated with ZR2 regimen for 3 cycles, followed by 3 cycles of immunochemotherapy, and zebrutinib maintenance therapy for 2 years after the end of induction therapy, in order to improve the remission rate and prognosis of patients with induction therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-08.
Trial Details
NCT Number NCT05992597
Lead Sponsor Zhejiang Cancer Hospital
Conditions Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
Enrollment 48 participants
Start Date 2022-08-01
Primary Completion 2025-08-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2023-09-21